Medindia

X

Bristol-Myers' Kidney Transplant Drug Nulojix Receives FDA Green Signal

by Kathy Jones on  June 16, 2011 at 7:32 PM Drug News   - G J E 4
The US Food and Drug Administration has approved Bristol-Myers' Nulojix, which is a drug that prevents organ rejection in kidney transplant patients.
 Bristol-Myers' Kidney Transplant Drug Nulojix Receives FDA Green Signal
Bristol-Myers' Kidney Transplant Drug Nulojix Receives FDA Green Signal
Advertisement

The new drug is to be used with other immunosuppressive drugs such as basiliximab, mycophenolate mofetil, and corticosteroids. Nulojix belongs to a class of drugs called selective T-cell costimulation blockers.

Advertisement
These drugs prevent the body from rejecting the newly transplanted kidney. The FDA approval follows the successful completion of two Phase-3 studies that included more than 1,200 patients. These studies compared two dose regimens of Nulojix with another immunosuppressant, cyclosporine.

Nulojix is an effective drug, but also carries a boxed warning regarding a risk of post-transplant lymphoproliferative disorder (PTLD), which is a type of cancer of the white blood cells.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All